{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:50:42Z","timestamp":1740142242345,"version":"3.37.3"},"reference-count":36,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"publisher","award":["IF\/00092\/2014\/ CP1255\/ CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/ CP1255\/ CT0004"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Science and Technology Foundation, FCT","doi-asserted-by":"publisher","award":["PD\/BD\/135458\/2017"],"award-info":[{"award-number":["PD\/BD\/135458\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2019,9,17]]},"abstract":"<jats:sec><jats:title\/><jats:p>Cationic antimicrobial peptides (CAMPs) can be considered as new potential therapeutic agents for Tuberculosis treatment with a specific amino acid sequence. New studies can be developed in the future to improve the pharmacological properties of CAMPs and also understand possible resistance mechanisms. This review discusses the principal properties of natural and\/or synthetic CAMPs, and how these new peptides have a significant specificity for Mycobacterium tuberculosis. Also, we propose some alternative strategies to enhance the therapeutic activity of these CAMPs that include coadministration with nanoparticles and\/or classic drugs.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389203720666190626160057","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T20:06:03Z","timestamp":1561579563000},"page":"885-892","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cationic Antimicrobial Peptides for Tuberculosis: A Mini-Review"],"prefix":"10.2174","volume":"20","author":[{"given":"Sara","family":"Silva","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]}],"member":"965","reference":[{"unstructured":"World Health Organization2016 Global Tuberculosis Report 2016. World Health Organizatio, Geneva, Switzerland. Available at: ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/250441\/1\/978924156-5394-eng.pdf?ua=1\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/250441\/1\/978924156-5394-eng.pdf?ua=1","key":"ref=1"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0167-7799(97)01156-6","volume":"16","author":"Hancock R.E.W.","year":"1998","unstructured":"Hancock R.E.W.; Lehrer R.; Cationic peptides: A new source of antibiotics. Trends Biotechnol 1998,16(2),82-88","journal-title":"Trends Biotechnol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.peptides.2015.05.012","volume":"72","author":"Lakshmaiah N.J.","year":"2015","unstructured":"Lakshmaiah N.J.; Chen J.Y.; Antimicrobial peptides: Possible anti-infective agents. Peptides 2015,72,88-94","journal-title":"Peptides"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/1040841X.2012.699025","volume":"39","author":"Anaya-L\u00f3pez J.L.","year":"2013","unstructured":"Anaya-L\u00f3pez J.L.; L\u00f3pez-Meza J.E.; Ochoa-Zarzosa A.; Bacterial resistance to cationic antimicrobial peptides. Crit Rev Microbiol 2013,39(2),180-195","journal-title":"Crit Rev Microbiol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/CMR.00056-05","volume":"19","author":"Jenssen H.","year":"2006","unstructured":"Jenssen H.; Hamill P.; Hancock R.E.W.; Peptide antimicrobial agents. Clin Microbiol Rev 2006,19(3),491-511","journal-title":"Clin Microbiol Rev"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/1386207053764558","volume":"8","author":"McPhee J.","year":"2005","unstructured":"McPhee J.; Scott M.; Hancock R.; Design of host defence peptides for antimicrobial and immunity enhancing activities. Comb Chem High Throughput Screen 2005,8(3),257-272","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1034\/j.1399-3003.2000.16a20.x","volume":"16","author":"Sharma S.","year":"2000","unstructured":"Sharma S.; Verma I.; Khuller G.K.; Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: In vitro and ex vivo study. Eur Respir J 2000,16(1),112-117","journal-title":"Eur Respir J"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/IAI.64.3.926-932.1996","volume":"64","author":"Miyakawa Y.","year":"1996","unstructured":"Miyakawa Y.; Ratnakar P.; Rao A.G.; Costello M.L.; Mathieu-Costello O.; Lehrer R.I.; Catanzaro A.; In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect Immun 1996,64(3),926-932","journal-title":"Infect Immun"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.peptides.2004.04.003","volume":"25","author":"Fattorini L.","year":"2004","unstructured":"Fattorini L.; Gennaro R.; Zanetti M.; Tan D.; Brunori L.; Giannoni F.; Pardini M.; Orefici G.; In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Peptides 2004,25(7),1075-1077","journal-title":"Peptides"},{"author":"Linde C.M.A.","unstructured":"Linde C.M.A.; Hoffner S.E.; Refai E.; Andersson M.; Susceptible and multi-drug-resistant Mycobacterium tuberculosis. 2001, 1, 575- 580.","key":"ref=10"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijantimicag.2012.09.015","volume":"41","author":"Rivas-Santiago B.","year":"2013","unstructured":"Rivas-Santiago B.; Rivas Santiago C.E.; Casta\u00f1eda-Delgado J.E.; Le\u00f3n-Contreras J.C.; Hancock R.E.W.; Hernandez-Pando R.; Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents 2013,41(2),143-148","journal-title":"Int J Antimicrob Agents"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/092986611794578288","volume":"18","author":"Jiang Z.","year":"2011","unstructured":"Jiang Z.; Higgins M.P.; Whitehurst J.; Kisich K.O.; Voskuil M.I.; Hodges R.S.; Anti-tuberculosis activity of \u03b1-helical antimicrobial peptides: De novo designed L- and D-enantiomers versus L- and D-LL37. Protein Pept Lett 2011,18(3),241-252","journal-title":"Protein Pept Lett"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.peptides.2012.04.018","volume":"36","author":"Santos P.","year":"2012","unstructured":"Santos P.; Gordillo A.; Osses L.; Salazar L.M.; Soto C.Y.; Effect of antimicrobial peptides on ATPase activity and proton pumping in plasma membrane vesicles obtained from mycobacteria. Peptides 2012,36(1),121-128","journal-title":"Peptides"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1007\/s00253-017-8466-3","volume":"101","author":"Sharma R.","year":"2017","unstructured":"Sharma R.; Saikia U.N.; Sharma S.; Verma I.; Activity of human beta defensin-1 and its motif against active and dormant Mycobacterium tuberculosis. Appl Microbiol Biotechnol 2017,101(19),7239-7248","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1128\/AAC.04054-14","volume":"59","author":"Gao W.","year":"2015","unstructured":"Gao W.; Kim J.Y.; Anderson J.R.; Akopian T.; Hong S.; Jin Y.Y.; Kandror O.; Kim J.W.; Lee I.A.; Lee S.Y.; McAlpine J.B.; Mulugeta S.; Sunoqrot S.; Wang Y.; Yang S.H.; Yoon T.M.; Goldberg A.L.; Pauli G.F.; Suh J.W.; Franzblau S.G.; Cho S.; The cyclic peptide ecumicin targeting CLpC1 is active against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2015,59(2),880-889","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.chembiol.2014.01.014","volume":"21","author":"Gavrish E.","year":"2014","unstructured":"Gavrish E.; Sit C.S.; Cao S.; Kandror O.; Spoering A.; Peoples A.; Ling L.; Fetterman A.; Hughes D.; Bissell A.; Torrey H.; Akopian T.; Mueller A.; Epstein S.; Goldberg A.; Clardy J.; Lewis K.; Lassomycin, a ribosomally synthesized cyclic peptide, kills Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem Biol 2014,21(4),509-518","journal-title":"Chem Biol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.peptides.2015.08.014","volume":"73","author":"Ram\u00edrez-Carreto S.","year":"2015","unstructured":"Ram\u00edrez-Carreto S.; Jim\u00e9nez-Vargas J.M.; Rivas-Santiago B.; Corzo G.; Possani L.D.; Becerril B.; Ortiz E.; Peptides from the scorpion Vaejovis punctatus with broad antimicrobial activity. Peptides 2015,73,51-59","journal-title":"Peptides"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0924-8579(03)00110-9","volume":"22","author":"Xie J.P.","year":"2003","unstructured":"Xie J.P.; Yue J.; Xiong Y.L.; Wang W.Y.; Yu S.Q.; Wang H.H.; In vitro activities of small peptides from snake venom against clinical isolates of drug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 2003,22(2),172-174","journal-title":"Int J Antimicrob Agents"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1021\/acs.jnatprod.5b00266","volume":"78","author":"Daletos G.","year":"2015","unstructured":"Daletos G.; Kalscheuer R.; Koliwer-Brandl H.; Hartmann R.; De Voogd N.J.; Wray V.; Lin W.; Proksch P.; Callyaerins from the marine sponge Callyspongia aerizusa: Cyclic peptides with antitubercular activity. J Nat Prod 2015,78(8),1910-1925","journal-title":"J Nat Prod"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijantimicag.2010.03.029","volume":"36","author":"Carroll J.","year":"2010","unstructured":"Carroll J.; Draper L.; O\u2019Connor P.M.; Coffey A.; Hill C.; Ross R.P.; Cotter P.D.; O\u2019Mahony J.; Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents 2010,36(2),132-136","journal-title":"Int J Antimicrob Agents"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1128\/AAC.00940-15","volume":"60","author":"Pearson C.S.","year":"2016","unstructured":"Pearson C.S.; Kloos Z.; Murray B.; Tabe E.; Gupta M.; Kwak J.H.; Karande P.; McDonough K.; Belfort G.; Combined bioinformatic and rational design approach to develop antimicrobial peptides against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2016,60(5),2757-2764","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1128\/AAC.00175-13","volume":"57","author":"Ram\u00f3n-Garc\u00eda S.","year":"2013","unstructured":"Ram\u00f3n-Garc\u00eda S.; Mikut R.; Ng C.; Ruden S.; Volkmer R.; Reischl M.; Hilpert K.; Thompson C.J.; Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother 2013,57(5),2295-2303","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.04.018","author":"Silva S.","year":"2019","unstructured":"Silva S.; Santos-Silva A.; Manuel Correia da Costa J.; Vale N.; Potent cationic antimicrobial peptides against Mycobacterium tuberculosis in vitro. J Glob Antimicrob Resist 2019","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1128\/AAC.01667-10","volume":"55","author":"Kapoor R.","year":"2011","unstructured":"Kapoor R.; Eimerman P.R.; Hardy J.W.; Cirillo J.D.; Contag C.H.; Barron A.E.; Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011,55(6),3058-3062","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.biomaterials.2013.10.053","volume":"35","author":"Ong Z.Y.","year":"2014","unstructured":"Ong Z.Y.; Cheng J.; Huang Y.; Xu K.; Ji Z.; Fan W.; Yang Y.Y.; Effect of stereochemistry, chain length and sequence pattern on antimicrobial properties of short synthetic\u202f\u03b2-sheet forming peptide amphiphiles. Biomaterials 2014,35(4),1315-1325","journal-title":"Biomaterials"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.biomaterials.2013.11.035","volume":"35","author":"Khara J.S.","year":"2014","unstructured":"Khara J.S.; Wang Y.; Ke X.Y.; Liu S.; Newton S.M.; Langford P.R.; Yang Y.Y.; Ee P.L.R.; Anti-mycobacterial activities of synthetic cationic \u03b1-helical peptides and their synergism with rifampicin. Biomaterials 2014,35(6),2032-2038","journal-title":"Biomaterials"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1016\/j.bmc.2016.06.048","volume":"24","author":"Hicks R.P.","year":"2016","unstructured":"Hicks R.P.; Antibacterial and anticancer activity of a series of novel peptides incorporating cyclic tetra-substituted c(\u03b1) amino acids. Bioorg Med Chem 2016,24(18),4056-4065","journal-title":"Bioorg Med Chem"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.tube.2014.08.001","volume":"94","author":"Lan Y.","year":"2014","unstructured":"Lan Y.; Lam J.T.; Siu G.K.H.; Yam W.C.; Mason A.J.; Lam J.K.W.; Cationic amphipathic d-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis. Tuberculosis 2014,94(6),678-689","journal-title":"Tuberculosis"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijpharm.2015.07.001","volume":"491","author":"Kwok P.C.L.","year":"2015","unstructured":"Kwok P.C.L.; Grabarek A.; Chow M.Y.T.; Lan Y.; Li J.C.W.; Casettari L.; Mason A.J.; Lam J.K.W.; Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. Int J Pharm 2015,491(1-2),367-374","journal-title":"Int J Pharm"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"Hancock R.E.W.","year":"2006","unstructured":"Hancock R.E.W.; Sahl H.G.; Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006,24(12),1551-1557","journal-title":"Nat Biotechnol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1586\/14787210.2014.976613","volume":"12","author":"Kang S.J.","year":"2014","unstructured":"Kang S.J.; Park S.J.; Mishig-Ochir T.; Lee B.J.; Antimicrobial peptides: Therapeutic potentials. Expert Rev Anti Infect Ther 2014,12(12),1477-1486","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jcis.2014.11.024","volume":"449","author":"Schmidtchen A.","year":"2015","unstructured":"Schmidtchen A.; Malmsten M.; (Lipo)polysaccharide interactions of antimicrobial peptides. J Colloid Interface Sci 2015,449,136-142","journal-title":"J Colloid Interface Sci"},{"key":"ref=33","first-page":"403","volume":"23","author":"Vale N.","year":"2018","unstructured":"Vale N.; Correia A.; Silva S.; Figueiredo P.; M\u00e4kil\u00e4 E.; Salonen J.; Hirvonen J.; Pedrosa J.; Santos H.A.; Fraga A.; Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis. Bioorg Med Chem Lett 2018,23(3),403-405","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1002\/ejoc.201500715","volume":"2015","author":"Vale N.","year":"2015","unstructured":"Vale N.; Veloso R.C.; Gomes P.; Exploring the solid\u2010phase synthesis of sulfotyrosine peptides. Eur J Org Chem 2015,2015(34),7413-7425","journal-title":"Eur J Org Chem"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.coph.2006.04.006","volume":"6","author":"Marr A.K.","year":"2006","unstructured":"Marr A.K.; Gooderham W.J.; Hancock R.E.W.; Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr Opin Pharmacol 2006,6(5),468-472","journal-title":"Curr Opin Pharmacol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drudis.2016.10.017","volume":"22","author":"da Cunha N.B.","year":"2017","unstructured":"da Cunha N.B.; Cobacho N.B.; Viana J.F.C.; Lima L.A.; Sampaio K.B.O.; Dohms S.S.M.; Ferreira A.C.R.; de la Fuente-N\u00fa\u00f1ez C.; Costa F.F.; Franco O.L.; Dias S.C.; The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts. Drug Discov Today 2017,22(2),234-248","journal-title":"Drug Discov Today"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T02:49:52Z","timestamp":1610074192000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173023\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389203720666190626160057","relation":{},"ISSN":["1389-2037"],"issn-type":[{"type":"print","value":"1389-2037"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}